• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中肝脏脂质积累的分子机制。

Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.

机构信息

Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Ridebanevej 9, 1870, Frederiksberg C, Denmark.

出版信息

Cell Mol Life Sci. 2018 Sep;75(18):3313-3327. doi: 10.1007/s00018-018-2860-6. Epub 2018 Jun 23.

DOI:10.1007/s00018-018-2860-6
PMID:29936596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6105174/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently the world's most common liver disease, estimated to affect up to one-fourth of the population. Hallmarked by hepatic steatosis, NAFLD is associated with a multitude of detrimental effects and increased mortality. This narrative review investigates the molecular mechanisms of hepatic steatosis in NAFLD, focusing on the four major pathways contributing to lipid homeostasis in the liver. Hepatic steatosis is a consequence of lipid acquisition exceeding lipid disposal, i.e., the uptake of fatty acids and de novo lipogenesis surpassing fatty acid oxidation and export. In NAFLD, hepatic uptake and de novo lipogenesis are increased, while a compensatory enhancement of fatty acid oxidation is insufficient in normalizing lipid levels and may even promote cellular damage and disease progression by inducing oxidative stress, especially with compromised mitochondrial function and increased oxidation in peroxisomes and cytochromes. While lipid export initially increases, it plateaus and may even decrease with disease progression, sustaining the accumulation of lipids. Fueled by lipo-apoptosis, hepatic steatosis leads to systemic metabolic disarray that adversely affects multiple organs, placing abnormal lipid metabolism associated with NAFLD in close relation to many of the current life-style-related diseases.

摘要

非酒精性脂肪性肝病(NAFLD)是目前世界上最常见的肝脏疾病,估计影响多达四分之一的人口。NAFLD 的特征是肝脂肪变性,与多种有害影响和死亡率增加有关。本综述探讨了 NAFLD 中肝脂肪变性的分子机制,重点关注导致肝脏脂质稳态的四大主要途径。肝脂肪变性是脂质摄取超过脂质处置的结果,即脂肪酸摄取和从头合成超过脂肪酸氧化和输出。在 NAFLD 中,肝摄取和从头合成增加,而脂肪酸氧化的代偿性增强不足以使脂质水平正常化,甚至可能通过诱导氧化应激促进细胞损伤和疾病进展,特别是在存在线粒体功能受损和过氧化物酶体和细胞色素中氧化增加的情况下。尽管脂质输出最初增加,但随着疾病的进展,它会趋于平稳甚至下降,从而维持脂质的积累。在脂凋亡的推动下,肝脂肪变性导致全身代谢紊乱,对多个器官产生不利影响,使与 NAFLD 相关的异常脂质代谢与许多当前与生活方式相关的疾病密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/f1f8c497b1ac/18_2018_2860_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/a78550726a4c/18_2018_2860_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/03f1df80d7d4/18_2018_2860_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/f1f8c497b1ac/18_2018_2860_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/a78550726a4c/18_2018_2860_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/03f1df80d7d4/18_2018_2860_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef41/11105735/f1f8c497b1ac/18_2018_2860_Fig3_HTML.jpg

相似文献

1
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中肝脏脂质积累的分子机制。
Cell Mol Life Sci. 2018 Sep;75(18):3313-3327. doi: 10.1007/s00018-018-2860-6. Epub 2018 Jun 23.
2
Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.法尼醇 X 受体在非酒精性脂肪性肝病肝脂肪变性中的作用。
Biomed Pharmacother. 2020 Jan;121:109609. doi: 10.1016/j.biopha.2019.109609. Epub 2019 Nov 12.
3
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.肝脏脂质蓄积:血糖调节激素失调的原因及后果
J Endocrinol. 2017 Jul;234(1):R1-R21. doi: 10.1530/JOE-16-0513. Epub 2017 Apr 20.
4
Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease.触发受体表达在髓样细胞 2 相关改变对非酒精性脂肪性肝病发展中巨噬细胞脂质代谢的影响。
J Gastroenterol Hepatol. 2024 Feb;39(2):369-380. doi: 10.1111/jgh.16417. Epub 2023 Nov 27.
5
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.非酒精性脂肪性肝炎发病机制中的脂质氧化产物。
Free Radic Biol Med. 2017 Oct;111:173-185. doi: 10.1016/j.freeradbiomed.2017.01.023. Epub 2017 Jan 18.
6
Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.
7
6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction.6-姜酚改善与年龄相关的肝脂肪变性:与调节脂肪生成、脂肪酸氧化、氧化应激和线粒体功能障碍有关。
Toxicol Appl Pharmacol. 2019 Jan 1;362:125-135. doi: 10.1016/j.taap.2018.11.001. Epub 2018 Nov 5.
8
Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.脂肪酸和氧化固醇的协同作用会损害线粒体功能,并限制非酒精性脂肪性肝病进展过程中的肝脏适应能力。
Redox Biol. 2018 May;15:86-96. doi: 10.1016/j.redox.2017.11.016. Epub 2017 Dec 5.
9
Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.线粒体在非酒精性脂肪性肝病中的作用的分子见解。
Arch Pharm Res. 2019 Nov;42(11):935-946. doi: 10.1007/s12272-019-01178-1. Epub 2019 Sep 30.
10
'Micro-managers' of hepatic lipid metabolism and NAFLD.肝脂代谢和非酒精性脂肪性肝病的“微观管理者”。
Wiley Interdiscip Rev RNA. 2015 Sep-Oct;6(5):581-93. doi: 10.1002/wrna.1295. Epub 2015 Jul 21.

引用本文的文献

1
Skeletal Muscle and Cardiovascular Health.骨骼肌与心血管健康。
Adv Exp Med Biol. 2025;1478:631-659. doi: 10.1007/978-3-031-88361-3_26.
2
Normalization of Oxygen Levels Induces a Metabolic Reprogramming in Livers Exposed to Intermittent Hypoxia Mimicking Obstructive Sleep Apnea.氧水平正常化会在模拟阻塞性睡眠呼吸暂停的间歇性低氧暴露的肝脏中诱导代谢重编程。
Antioxidants (Basel). 2025 Aug 7;14(8):971. doi: 10.3390/antiox14080971.
3
Hydrogen gas (H) delivered by intraperitoneal injection alleviated methionine- and choline-deficient diet-induced metabolic dysfunction-associated steatotic liver disease in mice via inhibiting GSDMD- and GSDME-mediated pyroptosis.

本文引用的文献

1
Preclinical models of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的临床前模型。
J Hepatol. 2018 Feb;68(2):230-237. doi: 10.1016/j.jhep.2017.10.031. Epub 2017 Nov 9.
2
Pharmacotherapy for NASH: Current and emerging.非酒精性脂肪性肝炎的药物治疗:现状与进展。
J Hepatol. 2018 Feb;68(2):362-375. doi: 10.1016/j.jhep.2017.10.015. Epub 2017 Nov 6.
3
Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide.非酒精性脂肪性肝病动物模型:入门指南。
腹腔注射氢气(H₂)通过抑制GSDMD和GSDME介导的细胞焦亡,减轻了蛋氨酸和胆碱缺乏饮食诱导的小鼠代谢功能障碍相关脂肪性肝病。
Front Pharmacol. 2025 Aug 8;16:1575106. doi: 10.3389/fphar.2025.1575106. eCollection 2025.
4
[Prevalence and associated factors of hyperuricemia in patients with type 2 diabetes in hospital settings in Dakar, Senegal].[塞内加尔达喀尔医院环境中2型糖尿病患者高尿酸血症的患病率及相关因素]
Pan Afr Med J. 2025 Jun 16;51:45. doi: 10.11604/pamj.2025.51.45.47695. eCollection 2025.
5
Association between dietary inflammatory index and hepatic steatosis: cross-sectional evidence from the NHANES 2007-2020.饮食炎症指数与肝脂肪变性之间的关联:来自2007 - 2020年美国国家健康与营养检查调查(NHANES)的横断面证据
J Health Popul Nutr. 2025 Aug 18;44(1):295. doi: 10.1186/s41043-025-01015-w.
6
Melatonin Prevents the Progression of MASLD via Inhibiting FFAs-Induced Ferroptosis through KEAP1/NRF2/HO-1 Pathway.褪黑素通过KEAP1/NRF2/HO-1途径抑制游离脂肪酸诱导的铁死亡来预防代谢相关脂肪性肝病的进展。
Biomol Ther (Seoul). 2025 Sep 1;33(5):876-889. doi: 10.4062/biomolther.2025.037. Epub 2025 Aug 18.
7
Dietary glycerol monolaurate mitigates heat stress-induced disruption of intestinal homeostasis and hepatic lipid metabolism in laying hens.日粮单月桂酸甘油酯可减轻热应激引起的蛋鸡肠道稳态破坏和肝脏脂质代谢紊乱。
Stress Biol. 2025 Aug 12;5(1):49. doi: 10.1007/s44154-025-00243-8.
8
Elevated hydrostatic pressure dysregulates lipid metabolism of hepatocytes.升高的流体静压会使肝细胞的脂质代谢失调。
J Physiol Biochem. 2025 Aug 11. doi: 10.1007/s13105-025-01121-7.
9
Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease.天然活性植物代谢产物:靶向AMPK信号通路治疗代谢功能障碍相关脂肪性肝病
Front Pharmacol. 2025 Jul 14;16:1611400. doi: 10.3389/fphar.2025.1611400. eCollection 2025.
10
Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives.活性氧作为酒精性脂肪性肝病和非酒精性脂肪性肝病发病机制中的关键分子:未来展望
Curr Issues Mol Biol. 2025 Jun 17;47(6):464. doi: 10.3390/cimb47060464.
Nutrients. 2017 Sep 27;9(10):1072. doi: 10.3390/nu9101072.
4
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.ASK1 抑制剂 selonsertib 治疗非酒精性脂肪性肝炎患者的随机、2 期临床试验。
Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26.
5
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.一项关于西尼利尤单抗治疗伴有纤维化的非酒精性脂肪性肝炎的随机、安慰剂对照试验。
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.
6
Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity.生脂转录因子ChREBP介导果糖诱导的代谢适应性变化以预防肝毒性。
J Clin Invest. 2017 Jun 30;127(7):2855-2867. doi: 10.1172/JCI89934. Epub 2017 Jun 19.
7
Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans.肝脏二酰甘油相关蛋白激酶Cε易位将人类肝脏脂肪变性与肝脏胰岛素抵抗联系起来。
Cell Rep. 2017 Jun 6;19(10):1997-2004. doi: 10.1016/j.celrep.2017.05.035.
8
Caveolin1 protects against diet induced hepatic lipid accumulation in mice.小窝蛋白1可防止小鼠因饮食诱导的肝脏脂质积累。
PLoS One. 2017 Jun 1;12(6):e0178748. doi: 10.1371/journal.pone.0178748. eCollection 2017.
9
Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.非酒精性脂肪性肝病与胰岛素抵抗:新见解及潜在新疗法
Nutrients. 2017 Apr 14;9(4):387. doi: 10.3390/nu9040387.
10
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.非酒精性脂肪性肝病及其与心血管病和其他肝外疾病的关系。
Gut. 2017 Jun;66(6):1138-1153. doi: 10.1136/gutjnl-2017-313884. Epub 2017 Mar 17.